Overview

Multiple Ascending Dose Study of BMS-929075 in Hepatitis C Virus (HCV) Infected Patients

Status:
Withdrawn
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the change from baseline in HCV Ribonucleic acid (RNA) on Day 4 following three days of dosing with BMS-929075 in chronically genotype subtype 1a and 1b HCV infected subjects
Phase:
Phase 1
Details
Lead Sponsor:
Bristol-Myers Squibb